These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32800724)

  • 1. Androgen Receptor Signaling Inhibitors in Nonmetastatic Castration-resistant Prostate Cancer and Risk of Cardiovascular Toxicity: All That Glitters Isn't Gold.
    Di Lorenzo G; Autorino R
    Eur Urol; 2020 Nov; 78(5):647-649. PubMed ID: 32800724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
    Esther J; Maughan BL; Anderson N; Agarwal N; Hahn AW
    Curr Treat Options Oncol; 2019 Feb; 20(2):14. PubMed ID: 30741354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer.
    Morgans AK; Shore N; Cope D; McNatty A; Moslehi J; Gomella L; Sartor O
    Urol Oncol; 2021 Jan; 39(1):52-62. PubMed ID: 32958445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents.
    Rizzo A; Oderda M; Mollica V; Merler S; Morelli F; Fragomeno B; Taveri E; Sorgentoni G; Santoni M; Massari F
    Anticancer Drugs; 2022 Jan; 33(1):e43-e51. PubMed ID: 34387593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K; Smith MR; Tombal B
    Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apalutamide for the treatment of metastatic castration-sensitive prostate cancer.
    Dror CM; Chi KN
    Future Oncol; 2020 Dec; 16(35):2905-2916. PubMed ID: 32885994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Darolutamide for treatment of castration-resistant prostate cancer.
    Rhea LP; Mendez-Marti S; Aragon-Ching JB
    Drugs Today (Barc); 2020 Mar; 56(3):185-193. PubMed ID: 32282865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer.
    Smith MR; Mehra M; Nair S; Lawson J; Small EJ
    Clin Genitourin Cancer; 2020 Apr; 18(2):e180-e189. PubMed ID: 31980408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How quality of life can help guide selection of androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.
    Smith MR
    Clin Adv Hematol Oncol; 2021 Oct; 19(10):627-630. PubMed ID: 34637427
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical observations regarding the use of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
    Oh WK
    Clin Adv Hematol Oncol; 2022 May; 20 Suppl 9(5):13-16. PubMed ID: 35579580
    [No Abstract]   [Full Text] [Related]  

  • 12. Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer: Q&A.
    Oh WK; Rettig MB
    Clin Adv Hematol Oncol; 2022 May; 20 Suppl 9(5):16-17. PubMed ID: 35579581
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent clinical trial data of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
    Beltran H
    Clin Adv Hematol Oncol; 2022 May; 20 Suppl 9(5):2-8. PubMed ID: 35579578
    [No Abstract]   [Full Text] [Related]  

  • 14. How patient characteristics can guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
    Rettig MB
    Clin Adv Hematol Oncol; 2022 May; 20 Suppl 9(5):9-12. PubMed ID: 35579579
    [No Abstract]   [Full Text] [Related]  

  • 15. Apalutamide shows efficacy in prostate cancer.
    Gourd E
    Lancet Oncol; 2018 Mar; 19(3):e149. PubMed ID: 29456088
    [No Abstract]   [Full Text] [Related]  

  • 16. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Lefebvre P; McQuarrie K; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2020 Jan; 37(1):512-526. PubMed ID: 31813087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review.
    Kunath F; Goebell PJ; Wullich B; Sikic D; Kahlmeyer A
    World J Urol; 2020 Mar; 38(3):601-611. PubMed ID: 30830274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
    Naito Y; Kato M; Kawanishi H; Yuguchi Y; Yuba T; Ishikawa T; Hattori K; Yamamoto A; Sano T; Matsukawa Y; Kimura T; Nishikimi T; Hattori R; Tsuzuki T; Gotoh M
    Prostate; 2020 Nov; 80(15):1373-1380. PubMed ID: 32914895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prostate cancer - enzalutamide extends survival].
    Aktuelle Urol; 2014 Mar; 45(2):98. PubMed ID: 24818263
    [No Abstract]   [Full Text] [Related]  

  • 20. Cases in the management of nonmetastatic castration-resistant prostate cancer: darolutamide as the first androgen receptor inhibitor in a fit, older man.
    Lowentritt BH
    Clin Adv Hematol Oncol; 2022 Jan; 20 Suppl 1(1):1-8. PubMed ID: 35343943
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.